News | January 30, 2026
Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Ryght AI tackles these hurdles with its AI Site Twin platform
Clinical trial enrollment has long been a bottleneck in drug development
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration turns kitting into a strategic advantage for sponsors and sites
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Subscribe To Our Newsletter & Stay Updated
